Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23605880 | 1.00 | GPR119 (0.43) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL29529911 | 1.00 | GPR119 (0.43) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL24399166 | 1.00 | GPR119 (0.43) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL30743365 | 0.94 | ALOX5AP (0.47) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL23579441 | 0.94 | ALOX5AP (0.47) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL26783267 | 0.94 | ALOX5AP (0.47) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL29529581 | 0.94 | ALOX5AP (0.47) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL7843338 | 0.88 | CHRNB2 (0.55) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL7410033 | 0.87 | GPR119 (0.43) | GPR119ALOX5APFEN1CHRNB2CHRNA4 | |
| SCHEMBL30743451 | 0.87 | GPR119 (0.43) | GPR119ALOX5APFEN1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| EP-4565584-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028316-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022094271-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | GPR119 1633/4885ALOX5AP 2807/4885FEN1 1873/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | GPR119 2987/4885ALOX5AP 4569/4885FEN1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.